generating.Given the strong suggestion of the efficacy as well as the safety and low expense of heparin, a prospective trial is warranted to compare low-dose heparin, low-molecular-weight heparin, or both with placebo and activated protein C in order to assess the relative contributions of these agents to the survival of patients with sepsis.We apologize for the oversight but wish to disclose that Drs.Davidson and Geerts have served as clinical investigators, consultants, or both for one or more of the following manufacturers of low-molecular-weight heparin: Aventis, Sanofi, and Pharmacia.
No takes yet. Share an insight, caveat, or question.
Stephen Waldek (2003) studied this question.